Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Glaxo Wellcome to broaden HIV/AIDS drug pipeline

Feb. 16, 1998

Development of HIV gene therapy discontinued

Feb. 13, 1998

Remune is safe and well tolerated in the treatment of HIV infection

Feb. 13, 1998

Safety and efficacy of thalidomide in HIV-positive patients

Feb. 13, 1998

Nutritional supplementation in HIV-infected patients

Feb. 13, 1998

Novel approach to HIV therapy described by ML Laboratories

Feb. 12, 1998

Panretin update

Feb. 12, 1998

Sustiva-containing combinations highly effective in reducing viral load in HIV-infected patients

Feb. 9, 1998

Promising laboratory findings and phase I results reported for Leukine

Feb. 6, 1998

Glaxo Wellcome's new NRTI highlighted at AIDS conference

Feb. 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...